dc.contributor.author | Marques, LVC | |
dc.contributor.author | Noronha, EP | |
dc.contributor.author | Andrade, FG | |
dc.contributor.author | Dos Santos-Bueno, FV | |
dc.contributor.author | Mansur, MB | |
dc.contributor.author | Terra-Granado, E | |
dc.contributor.author | Pombo-de-Oliveira, MS | |
dc.coverage.spatial | Switzerland | |
dc.date.accessioned | 2023-09-19T10:03:16Z | |
dc.date.available | 2023-09-19T10:03:16Z | |
dc.date.issued | 2018-10-31 | |
dc.identifier | ARTN 488 | |
dc.identifier.citation | Frontiers in Oncology, 2018, 8 pp. 488 - | |
dc.identifier.issn | 2234-943X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5975 | |
dc.identifier.eissn | 2234-943X | |
dc.identifier.eissn | 2234-943X | |
dc.identifier.doi | 10.3389/fonc.2018.00488 | |
dc.description.abstract | CD44 is a glycoprotein expressed in leucocytes and a marker of leukemia-initiating cells, being shown to be important in the pathogenesis of T cell acute lymphoblastic leukemia (T-ALL). In this study, we have (i) identified the aberrant antigenic pattern of CD44 and its isoform CD44v6 in T-ALL; (ii) tested the association with different T-cell subtypes and genomic alterations; (iii) identified the impact of CD44 status in T-ALL outcome. Samples from 184 patients (123 T-ALL and 61 AML; <19 years) were analyzed throughout multiparametric flow cytometry. Mutations in N/KRAS, NOTCH1, FBXW7 as well as STIL-TAL1 and TLX3 rearrangements were detected using standard molecular techniques. CD44 expression was characterized in all T-ALL and AML cases. Compared with AML samples in which the median fluorescence intensity (MFI) was 79.1 (1-1272), T-ALL was relatively low, with MFI 43.2 (1.9-1239); CD44v6 expression was rarely found, MFI 1 (0.3-3.7). T-ALL immature subtypes (mCD3/CD1aneg) had a lower CD44 expression, MFI 57.5 (2.7-866.3), whereas mCD3/TCRγδpos cases had higher expressions, MFI 99.9 (16.4-866.3). NOTCH1 mut and STIL-TAL1 were associated with low CD44 expression, whereas N/KRAS mut and FBXW7 mut cases had intermediate expression. In relation to clinical features, CD44 expression was associated with tumor infiltrations (p = 0.065). However, no association was found with initial treatment responses and overall survival prediction. Our results indicate that CD44 is aberrantly expressed in T-ALL being influenced by different genomic alterations. Unraveling this intricate mechanism is required to place CD44 as a therapeutic target in T-ALL. | |
dc.format | Electronic-eCollection | |
dc.format.extent | 488 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | FRONTIERS MEDIA SA | |
dc.relation.ispartof | Frontiers in Oncology | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | CD44 | |
dc.subject | CD44/CD44v6 | |
dc.subject | NOTCH1 | |
dc.subject | T-cell leukemia | |
dc.subject | acute myeloid leukemia | |
dc.title | CD44 Expression Profile Varies According to Maturational Subtypes and Molecular Profiles of Pediatric T-Cell Lymphoblastic Leukemia. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-10-10 | |
dc.date.updated | 2023-09-19T09:50:09Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.3389/fonc.2018.00488 | |
rioxxterms.licenseref.startdate | 2018-10-31 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/30430079 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Biology of Childhood Leukaemia | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.3389/fonc.2018.00488 | |
pubs.volume | 8 | |
icr.provenance | Deposited by Dr Marcela Braga Mansur on 2023-09-19. Deposit type is initial. No. of files: 1. Files: CD44 Expression Profile Varies According to Maturational Subtypes and Molecular Profiles of Pediatric T-Cell Lymphoblastic L.pdf | |